semaglutide fda approval approves obesity drug that helped people cut weight 15% FDA approves once-a-week diabetes shot

Altered warfarin metabolism in iron-deficient patient

Novo Nordisk is the market leader: Ozempic (weekly injection for type 2 diabetes) Wegovy (higher-dose weekly injection for obesity) Rybelsus ( Oral tablets for diabetes Oral tablets for weight management is in phase 3 trials) Eli Lilly is the other major player: Mounjaro (weekly injection for type 2 diabetes) Zepbound (higherdose weekly injection for obesity) This duopoly meant that both stocks had an incredible run-up from 2020 to 2024

Stimulants phenylephrine and pseudoephedrine aren't banned

What amount of residual gastric contents increases the risk of aspiration

Mistake 5: Falling for "natural GLP-1" marketing language The phrase "natural GLP-1" has become a marketing weapon

doi: 10.3389/fphar.2021.643972 17 BarrosA